Compare IMCR & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | NEOG |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2016 | 1995 |
| Metric | IMCR | NEOG |
|---|---|---|
| Price | $28.59 | $8.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $66.33 | $10.67 |
| AVG Volume (30 Days) | 369.3K | ★ 2.1M |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.25 | 0.02 |
| Revenue | $249,428,000.00 | ★ $894,661,000.00 |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | ★ $118.60 | $452.25 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.47 | $4.53 |
| 52 Week High | $40.71 | $11.43 |
| Indicator | IMCR | NEOG |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 39.48 |
| Support Level | $28.90 | $8.24 |
| Resistance Level | $34.35 | $10.12 |
| Average True Range (ATR) | 1.31 | 0.36 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 35.41 | 7.26 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.